Effect of Olanzapine on Clinical and Polysomnography Profiles in Patients with Schizophrenia

Table 3

Comparison of pre- and posttreatment polysomnography parameters (Wilcoxon Signed-Ranks Test–Monte Carlo Method; ).

Sleep variables	Pretreatment; (Mean ± SD)	Posttreatment; (Mean ± SD)		(2-tailed)
Total sleep period (min)	380.43 ± 113.80	440.90 ± 41.55	−1.278	0.210
Total sleep time (min)	263.83 ± 128.83	391.32 ± 47.15	−2.669
Sleep efficiency (%)	64.01 ± 23.36	82.38 ± 10.27	−2.784
Sleep onset latency (min)	12.90 ± 20.32	21.68 ± 12.90	−1.420	0.169
Stage 1 shifts	22.33 ± 9.22	26.00 ± 5.70	−0.712	0.486
Stage shifts	78.40 ± 32.40	84.53 ± 25.90	−0.142	0.896
Awakenings	13.93 ± 8.78	10.13 ± 8.32	−1.279	0.214
Stage 1 duration	70.10 ± 44.18	106.96 ± 28.02	−2.158
Stage 1 total sleep time (%)	29.90 ± 16.82	27.56 ± 7.08	−0.114	0.931
Stage 2 duration	124.40 ± 88.61	140.20 ± 63.28	−0.454	0.672
Stage 2 total sleep time (%)	45.94 ± 18.61	35.31 ± 14.70	−1.676	0.099
Stage 2 latency	25.93 ± 67.12	17.66 ± 27.02	−1.307	0.204
Stage 3 duration	30.63 ± 20.88	50.60 ± 27.0	−2.215
Stage 3 total sleep time (%)	11.56 ± 8.25	13.52 ± 8.81	−0.511	0.634
Stage 3 latency	96.40 ± 84.70	49.63 ± 50.58	−1.350	0.195
Stage 4 duration	3.23 ± 5.54	11.02 ± 11.92	−2.668
Stage 4 total sleep time (%)	1.16 ± 2.20	2.83 ± 3.0	−2.080
Stage 4 latency	166.92 ± 125.10	72.62 ± 52.73	−1.992	0.059
Number of REMs	2.47 ± 1.35	3.93 ± 1.22	−2.790
REM duration	35.47 ± 36.30	82.53 ± 45.94	−3.067
REM total sleep time (%)	11.43 ± 8.65	20.77 ± 10.32	−2.755
REM latency	169.82 ± 118.11	120.66 ± 49.64	−1.287	0.214

, .